Introdução: No Brasil, a leishmaniose tegumentar americana (LTA) é uma importante antropozoonose endêmica na maioria das regiões do país. Apesar da expansão da doença nos últimos anos, a LTA continua a ser uma doença negligenciada. A leishmaniose mucosa (LM) tem como principal agente causador a Leishmania (V.) brasilienses, e habitualmente ocorre meses ou anos após a infecção cutânea sintomática ou assintomática. Aproximadamente 5% dos pacientes com leishmaniose cutânea não tratada adequadamente irão desenvolver a LM, forma que causa importante morbidade aos pacientes. A LM é uma doença progressiva, que acomete cartilagens e estruturas ósseas da face, faringe e laringe. Complicações associadas à leishmaniose mucosa já foram descritas, embora não existam estudos que avaliem as alterações estruturais da face e seios paranasais utilizando métodos radiológicos e que estimem a prevalência de sinusopatia nesta população ou que a compare com a população geral. Objetivo: Avaliar o grau de opacificação dos seios paranasais em pacientes com leishmaniose mucosa tratada, assim como eventuais alterações anatômicas na face associadas à LM, através de tomografia computadorizada multislice (TCM) dos seios paranasais e comparar os achados encontrados nesta população com um grupo controle formado por pacientes que realizaram TCM de órbita. Este estudo também tem o escopo de determinar a prevalência de sinusopatia crônica nos pacientes com LM pós-tratamento, bem como encontrar prováveis variáveis preditoras que possam estar relacionadas com a gravidade da sinusopatia e das alterações tomográficas encontradas. Métodos: Foram avaliados 54 pacientes com LM tratada, que foram submetidos à TCM dos seios da face, e comparados com grupo controle de 40 pacientes que realizaram TCM de órbita. A análise das tomografias foi realizada a partir de reconstruções multiplanares nos planos axial, coronal e sagital. Foram avaliados o grau de opacificação (sinusopatia) dos seios paranasais, bem como a existência de eventuais alterações na face que pudessem estar relacionadas à LM. O grau de sinusopatia foi estabelecido seguindo-se os critérios de Lund-Mackay, segundo os quais foram atribuídos um valor para o grau de opacificação de cada sistema sinusal e dos complexos ostiomeatais, comparando o score dos casos com o dos controles. Posteriormente foi realizada uma análise comparativa entre os pacientes do grupo leishmaniose mucosa, que foram divididos em dois subgrupos, de acordo com a presença (Lund-Mackay >= 4) ou ausência (Lund-Mackay < 4) de doença sinusal, sendo 40 e 14 pacientes respectivamente. Após esta divisão foram feitas análises univariadas exploratórias em busca de variáveis preditoras que pudessem estar associadas com uma maior gravidade de sinusopatia apresentada. O nível de significância foi estabelecido com p<0,05. Resultados: Quarenta dos 54 pacientes com antecedente de LM (74,1%) apresentaram score tomográfico compatível com sinusopatia crônica (Lund-Mackay >= 4). Os pacientes do grupo leishmaniose mucosa apresentaram maior score de Lund-Mackay que os pacientes do grupo controle, bem como maior número de alterações na TCM dos seios paranasais, provavelmente associadas à leishmaniose. Estes pacientes também apresentaram graus mais severos de opacificação parcial e espessamento mucoso pansinusal 23/54 (42.6%). Além disso, opacificação total de pelo menos um dos seios paranasais só foi observada nos pacientes do grupo leishmaniose mucosa. Os pacientes com leishmaniose com score de Lund-Mackay >= 4 apresentaram maior tempo de sintomas até o primeiro tratamento e doença mais grave no momento do diagnóstico, sendo portanto prováveis variáveis preditoras de gravidade da sinusopatia. Conclusão: As tomografias computadorizadas dos seios paranasais dos pacientes com LM apresentaram diversas alterações estruturais, demonstrando o poder destrutivo desta doença. A alta prevalência de sinusite crônica observada nas tomografias computadorizadas desses pacientes quando comparados ao grupo controle, sugere que a LM pode ser um fator de risco para o desenvolvimento de sinusite crônica nesta população. Sexo masculino, tempo de sintomas até o primeiro tratamento e gravidade da LM no momento do diagnóstico podem ser consideradas prováveis variáveis preditoras de sinusite crônica nesses pacientes / Introduction: American tegumentary leishmaniasis (ATL) is an important anthropozoonosis that is endemic in most regions in Brazil. Despite the spread of the disease in recent years, ATL remains a neglected disease. Mucosal leishmaniasis (ML) is mainly caused by Leishmania (V.) brasiliensis agent, and usually occurs months or years after symptomatic or asymptomatic skin infection. Approximately 5% of patients with untreated cutaneous leishmaniasis will develop ML, a presentation that causes significant morbidity to patients. The mucosal leishmaniasis is a progressive disease that affects cartilage and bone structures of the nose and paranasal sinuses as well as other upper respiratory tract structures. Complications associated with ML have been described, but there is a lack of studies which evaluate the structural changes of the nose and paranasal sinuses in ML using radiological methods. Objective: To assess the degree of opacification of the paranasal sinuses in patients with treated mucosal leishmaniasis as well as any anatomic changes in the face associated with ML through multidector computed tomography scans (MDCT) of the sinuses, and compare the findings in this population with a control group. This study also aims at determining the prevalence of chronic sinusitis in patients with treated ML as well as finding probable predictive variables that may be related to the severity of sinus disease and CT findings. Methods: We evaluated 54 patients with treated ML who were submitted to MDCT of the sinuses, and compared with a control group of 40 patients who underwent MDCT of orbit. Analysis of the scans was performed from multiplanar reconstructions in the axial, coronal and sagittal views. The degree of sinus disease was assessed according to the Lund-Mackay criteria, in which a value was assigned to the degree of opacification of each sinus system and ostiomeatal complexes, and the scores from the mucosal leishmaniasis group were compared to the control group. A comparative analysis was then performed among patients in the mucosal leishmaniasis group, who were divided into 2 subgroups according to the presence (Lund-Mackay >= 4) or absence (Lund-Mackay < 4) of sinus disease, with 40 and 14 patients respectively. Following this subdivision, exploratory univariate analysis were performed to identify predictive variables that could be associated to the presentation of greater severity of sinus disease. The level of significance was defined as p <0.05. Results: Forty of the 54 patients with a history of ML (74.1%) had a tomographic score compatible with chronic sinusitis (Lund- Mackay >= 4). CT scans in the leishmaniasis and control groups demonstrated significant differences in terms of facial structural alterations. Patients from the mucosal leishmaniasis group showed more severe levels of partial opacification and pan sinus mucosal thickening 23/54 (42.6%), furthermore complete opacification of at least one paranasal sinus was only observed in the leismaniasis group. Patients from the mucosal leishmaniasis group with Lund-Mackay score >= 4 presented greater length of symptoms before treatment and more severe presentation of the disease at the diagnosis. Conclusion: CT scans of the sinus of patients with ML also presented several structural alterations, expressing the prominent destructive feature of the disease. The higher prevalence of chronic rhinosinusitis observed in CT scans of patients with treated ML in this study when compared to the control group suggests that ML can be seen as a risk factor for chronic rhinosinusitis in this population. Male sex, having the disease for more than two years before first treatment and/or a more severe presentation of ML at diagnosis, can be considered as predictive variables of chronic sinusitis in these patients

INTRODUÇÃO: O câncer colorretal (CCR) é doença de grande importância, com elevada incidência e mortalidade. Restrito às camadas mucosa e submucosa, é denominado CCR precoce, sendo passível de tratamento endoscópico curativo na ausência de fatores de risco para metástases linfonodais. Entretanto, as técnicas para tal não são universalmente disponíveis, e muitos destes pacientes são tratados por ressecções cirúrgicas. OBJETIVO: Buscar estudos com os resultados do tratamento cirúrgico e endoscópico do CCR precoce e compará-los por meio de metanálise. MÉTODOS: Foi efetuada busca nas bases MEDLINE, EMBASE, LILACS, CENTRAL COCHRANE e EBSCO por estudos comparativos que incluíram pacientes com CCR precoce, submetidos a tratamento endoscópico ou cirúrgico. Dados de mortalidade, recidiva a longo prazo, taxas de ressecção em bloco e ressecção curativa, tempo de procedimento, taxas de complicações e complicações graves foram extraídos. Viés foi individualmente avaliado pela escala de Newcastle-Ottawa. Foram efetuados cálculos do risco absoluto (RA), seu aumento (ARA) ou redução (RAA), e dos números necessários para causar dano (NNH) ou tratar (NNT), com intervalo de confiança (IC) de 95% para significância estatística. Para metanálise dos dados, foi utilizado o programa RevMan 5, com uso do teste de Mantel-Haenszel para calcular um IC de 95%, e expressão dos resultados em gráficos de forest e funnel plot. A consistência entre os estudos foi relatada por I2. RESULTADOS: Foram encontradas 12.905 entradas via PUBMED e 12.818 via outras bases. Após remoção de duplicatas e aplicação dos critérios de inclusão e exclusão, restaram quatro estudos de coorte retrospectiva. Não foi observada diferença para mortalidade (339 pacientes) ou recorrência a longo prazo (577 pacientes). Foi observada superioridade do tratamento cirúrgico em 11% (-0,11 [IC 95% -0,14; -0,09, P < 0,05]) para taxa de ressecção em bloco (1.085 pacientes), e em 11% (-0,11 [IC 95% -0,21; -0,02, P < 0,05]) para taxa de ressecção curativa (1.112 pacientes). O tratamento endoscópico demonstrou superioridade de 7% (-0,07 [IC 95% -0,10; -0,03]) para taxa de complicações (1.085 pacientes), de 8% (-0,08 [IC 95% -0,15; -0,01]) para complicações graves (827 pacientes), e de 130 minutos (-130,34 [IC 95% -190,5; -70,17, P < 0,05) para tempo de procedimento (827 pacientes). CONCLUSÃO: Conforme os dados disponíveis na literatura, o tratamento do CCR precoce apresenta melhores resultados pela técnica cirúrgica quanto às taxas de ressecção em bloco e curativa, e menos complicações e menor tempo de procedimento pela técnica endoscópica. Não há diferença quanto às taxas de mortalidade e recidiva a longo prazo / INTRODUCTION: Colorectal cancer (CRC) represents an important disease, with high incidence and mortality. When restricted to the mucosa and submucosa it is called early CRC, with curative endoscopic treatment in the absence of histopathological conditions associated with high risk of linfonodal metastasis. However, such treatment techniques are not widely available, and many of these patients undergo surgical resection. OBJECTIVES: To search for studies of endoscopic and surgical treatment modalities for early CRC, and compare these results through meta-analysis. METHODS: MEDLINE, EMBASE, LILACS, CENTRAL COCHRANE, and EBSCO databases were searched for comparative studies, which included early CRC patients subjected to surgical or endoscopic treatments. Data regarding mortality, recurrence, en bloc resection rate, curative resection rate, procedure time, complications rate, and severe complications rate were extracted. Study bias was evaluated using the Newcastle-Ottawa score. Absolute Risk (AR), AR reduction (ARR), AR increase (ARI), and the number necessary to treat (NNT) or to harm (NNH) were computed, using a 95% confidence interval (CI) as statistically significant. RevMan 5 software was used for meta-analysis, applying Mantel-Haenszel tests to achieve a 95% CI; results were represented by forest and funnel plots. Consistency among studies was reported via I2. RESULTS: 12,905 entries were found via PUBMED, and 12,818 via other databases. After removal of duplicates and observation of inclusion and exclusion criteria, 4 retrospective cohort studies were considered for analysis. No differences in mortality (339 patients) and long-term recurrence (577) were observed between the two groups. Surgical treatment had higher rates of en bloc resection (-0.11 [95% CI -0.14, -0.09, P < 0.05] - 1,085 patients) and curative resection (-0.11 [IC 95% CI -0.21, - 0.02, P < 0.05] - 1,112 patients) when compared to endoscopic treatment. Endoscopic treatment had lower total complication rate (0.07 [IC 95% -0.10; - 0.03] - 1,085 patients), lower severe complication rate (-0.08 [IC 95% -0.15; - 0.01] - 827 patients), and shorter procedure time than the surgical treatment (-130.34 min [IC 95% -190.5; -70.17, P < 0.05] - 827 patients). CONCLUSION: According to available data, surgical treatment of early CRC yields better results regarding en bloc resection and curative resection rates; endoscopic treatment of early CRC results in lower complication rate and shorter procedure time. There are no differences in mortality and long-term recurrence rates

L’avènement des multi-thérapies antirétrovirales a permis une réduction importante de la mortalité associée au VIH en induisant notamment la chute de la charge virale à moins de 50 copies/mL et une récupération progressive du nombre de lymphocytes T CD4+ (LT-CD4). Cependant, certains patients définis comme mauvais répondeurs immunologiques (MRI) ne parviennent pas à récupérer un taux de CD4 généralement considéré comme « protecteur » (>500cellules/µL). L’interleukine-7 (IL-7), cytokine essentielle à la thymopoïèse et à l’homéostasie lymphocytaire T, a été utilisée en étude clinique afin de restaurer et maintenir le taux de LT-CD4 chez les patients MRI. La première partie de mon travail de thèse visait à évaluer l’impact d’une telle thérapie sur le réservoir viral circulant. Dans l’essai clinique sur lequel nous avons travaillé (INSPIRE 3, Cytheris), des cycles d’administration d’IL-7 ont induit une augmentation significative du nombre de LT-CD4 et CD8 circulants, avec une expansion majoritaire des populations naïves et centrales mémoires. Nous avons montré qu’un cycle d’injections d’IL-7 induisait une augmentation significative de la quantité de cellules infectées circulantes 28 jours et 3 mois post-injection. Cependant, malgré l’accroissement de la fréquence de LT-CD4 infectés 28 jours post-injection, nous avons observé une diminution significative de la charge virale ADN par million de LT-CD4 chez la majorité des patients 3 mois après l’initiation de la thérapie, suggérant une élimination partielle de cellules infectées. Suite au second cycle d’injections, nous n’avons pas observé d’évolution de la quantité de cellules infectées circulantes ni de la fréquence de LT-CD4 infectés, suggérant un impact différent des 2 cycles d’injections sur la dynamique du réservoir viral périphérique. Enfin, certains patients ayant développé des anticorps neutralisants anti-IL-7 (Nab) suite au second cycle d’injections d’IL-7, nous avons cherché à identifier des facteurs prédictifs de l’apparition de ces anticorps ainsi que leurs conséquences physiologiques in vivo. Le seul paramètre caractérisant ces patients est l’amplitude de la reconstitution T-CD4 au cours du premier cycle d’injections d’IL-7. Il semble donc qu’une meilleure réponse à l’IL-7 ait pour conséquence de faciliter le développement de la réponse immune contre cette cytokine. Cependant, ces anticorps ne sont détectables que de façon transitoire chez les patients. De plus, nous avons observé une diminution significative, mais transitoire, de la prolifération des thymocytes chez les patients présentant des Nab, démontrant un impact fonctionnel de ces anticorps sur l’activité biologique de l’IL-7 endogène. L’injection systémique d’IL-7 induit la migration des cellules circulantes vers différents compartiments tissulaires lymphoïdes et non lymphoïdes. Dans une seconde partie de mon travail de thèse, j’ai étudié le pouvoir adjuvant de cette cytokine administrée localement par pulvérisation à la surface de la muqueuse vaginale. Dans le modèle macaque rhésus, nous avons mis en évidence une augmentation de la production d’un large spectre de chimiokines dans le chorion et l’épithélium vaginal des animaux 48 heures après l’administration vaginale d’IL-7. Cette surexpression de chimiokines s’accompagne d’une migration massive de LT-CD4, CD8, macrophages, cellules dendritiques et cellules NK dans cette muqueuse, suggérant l’augmentation de la vigilance immunologique. L’effet adjuvant de cette cytokine a été confirmé par l’analyse de la réponse humorale muqueuse de macaques vaccinés par pulvérisation vaginale d’antigènes 48h après l’administration du spray d’IL-7. Dans les lavages cervicovaginaux (CVL) des animaux traités à l’IL-7, nous avons mis en évidence des réponses spécifiques de type IgA et IgG plus rapides, plus fortes et plus durables que chez les animaux contrôles, démontrant la capacité de l’IL-7 à préparer la muqueuse vaginale à répondre à une stimulation antigénique locale. / Highly Active Antiretroviral Therapy (HAART) has led to significant reduction of HIV-associated mortality by maintaining an undetectable viral load and inducing progressive CD4-T cell restoration. However, some patients, defined as poor immunological responders (PIR), fail to restore their CD4 counts to 500cells/µL during treatment, a threshold considered as the protective against AIDS related or non AIDS related malignancies, opportunistic infections and cardiovascular events. Interleukin-7 (IL-7), an essential cytokine for thymopoïesis and T cell homeostasis has been used in clinical trials aimed at restoring and maintaining CD4 counts in PIR patients. The first part of my thesis project aimed at assessing the impact of IL-7 therapy on circulating HIV reservoir. In the clinical study we worked on (INSPIRE 3, Cytheris), cycles of IL-7 injections led to a significant increase of the number of circulating CD4 and CD8 T-cells, with a predominance of naïve and central memory T cell expansion. We have shown that one cycle of IL-7 injections induced a significant increase in the number of circulating infected cells 28 days and 3 months post-injections. However, despite a significant increase in the frequency of infected CD4 T-cells 28 days post-injections, we observed a significant decrease of HIV-DNA load in CD4 T-cells in the majority of patients 3 months after the therapy initiation. These data suggest a partial elimination of HIV infected cells. After the second cycle of IL-7 injections, we did not observed any change in the number or frequency of circulating infected cells, suggesting a differential impact of the two IL-7 injection cycles on the dynamics of circulating HIV-reservoir. Finally, considering that some patients developed anti-IL-7 neutralizing antibodies (Nab) after the second cycle of IL-7 injections, we looked for predictive factors of this immunogenicity and analyzed its physiological consequences in vivo. The only parameter that distinguished Nab and non-Nab patients was the extent of CD4 T-cell reconstitution during the first cycle of therapy. This suggests that a better response to IL-7 also facilitates the development of auto-antibodies to the cytokine. However, these antibodies were only transiently detectable after the second cycle of therapy. Moreover, the appearance of Nab was associated with a significant but transient decrease of thymocyte proliferation, suggesting a functional impact of these antibodies on the endogenous IL-7 function. Systemic injection of IL-7 induces circulating T cells homing from the blood into lymphoid and non-lymphoid tissues. In the second part of my thesis project, I evaluated whether this cytokine could be used as an adjuvant when sprayed on the vaginal mucosa. Ten micrograms of IL-7 directly sprayed in the vaginal tract of rhesus monkeys induced, 48h after administration, the production of a large pattern of chemokines in the vaginal chorion and epithelium. This chemokine expression was accompanied by massive homing of CD4 and CD8-T cells, macrophages, dendritic cells and NK cells in the vaginal mucosa, suggesting an increased immunological vigilance. Finally, the adjuvant potential of this cytokine was confirmed by analyzing local humoral immune response after vaginal administration of antigens 48h following IL-7 spray. In cervicovaginal washes (CVL) of treated animals, we observed a faster, stronger and longer-lasting specific IgA and IgG response than in control animals, highlighting the capacity of IL-7 to prepare the vaginal mucosa response to local antigen stimulation.

Introdução: No Brasil, a leishmaniose tegumentar americana (LTA) é uma importante antropozoonose endêmica na maioria das regiões do país. Apesar da expansão da doença nos últimos anos, a LTA continua a ser uma doença negligenciada. A leishmaniose mucosa (LM) tem como principal agente causador a Leishmania (V.) brasilienses, e habitualmente ocorre meses ou anos após a infecção cutânea sintomática ou assintomática. Aproximadamente 5% dos pacientes com leishmaniose cutânea não tratada adequadamente irão desenvolver a LM, forma que causa importante morbidade aos pacientes. A LM é uma doença progressiva, que acomete cartilagens e estruturas ósseas da face, faringe e laringe. Complicações associadas à leishmaniose mucosa já foram descritas, embora não existam estudos que avaliem as alterações estruturais da face e seios paranasais utilizando métodos radiológicos e que estimem a prevalência de sinusopatia nesta população ou que a compare com a população geral. Objetivo: Avaliar o grau de opacificação dos seios paranasais em pacientes com leishmaniose mucosa tratada, assim como eventuais alterações anatômicas na face associadas à LM, através de tomografia computadorizada multislice (TCM) dos seios paranasais e comparar os achados encontrados nesta população com um grupo controle formado por pacientes que realizaram TCM de órbita. Este estudo também tem o escopo de determinar a prevalência de sinusopatia crônica nos pacientes com LM pós-tratamento, bem como encontrar prováveis variáveis preditoras que possam estar relacionadas com a gravidade da sinusopatia e das alterações tomográficas encontradas. Métodos: Foram avaliados 54 pacientes com LM tratada, que foram submetidos à TCM dos seios da face, e comparados com grupo controle de 40 pacientes que realizaram TCM de órbita. A análise das tomografias foi realizada a partir de reconstruções multiplanares nos planos axial, coronal e sagital. Foram avaliados o grau de opacificação (sinusopatia) dos seios paranasais, bem como a existência de eventuais alterações na face que pudessem estar relacionadas à LM. O grau de sinusopatia foi estabelecido seguindo-se os critérios de Lund-Mackay, segundo os quais foram atribuídos um valor para o grau de opacificação de cada sistema sinusal e dos complexos ostiomeatais, comparando o score dos casos com o dos controles. Posteriormente foi realizada uma análise comparativa entre os pacientes do grupo leishmaniose mucosa, que foram divididos em dois subgrupos, de acordo com a presença (Lund-Mackay >= 4) ou ausência (Lund-Mackay < 4) de doença sinusal, sendo 40 e 14 pacientes respectivamente. Após esta divisão foram feitas análises univariadas exploratórias em busca de variáveis preditoras que pudessem estar associadas com uma maior gravidade de sinusopatia apresentada. O nível de significância foi estabelecido com p<0,05. Resultados: Quarenta dos 54 pacientes com antecedente de LM (74,1%) apresentaram score tomográfico compatível com sinusopatia crônica (Lund-Mackay >= 4). Os pacientes do grupo leishmaniose mucosa apresentaram maior score de Lund-Mackay que os pacientes do grupo controle, bem como maior número de alterações na TCM dos seios paranasais, provavelmente associadas à leishmaniose. Estes pacientes também apresentaram graus mais severos de opacificação parcial e espessamento mucoso pansinusal 23/54 (42.6%). Além disso, opacificação total de pelo menos um dos seios paranasais só foi observada nos pacientes do grupo leishmaniose mucosa. Os pacientes com leishmaniose com score de Lund-Mackay >= 4 apresentaram maior tempo de sintomas até o primeiro tratamento e doença mais grave no momento do diagnóstico, sendo portanto prováveis variáveis preditoras de gravidade da sinusopatia. Conclusão: As tomografias computadorizadas dos seios paranasais dos pacientes com LM apresentaram diversas alterações estruturais, demonstrando o poder destrutivo desta doença. A alta prevalência de sinusite crônica observada nas tomografias computadorizadas desses pacientes quando comparados ao grupo controle, sugere que a LM pode ser um fator de risco para o desenvolvimento de sinusite crônica nesta população. Sexo masculino, tempo de sintomas até o primeiro tratamento e gravidade da LM no momento do diagnóstico podem ser consideradas prováveis variáveis preditoras de sinusite crônica nesses pacientes / Introduction: American tegumentary leishmaniasis (ATL) is an important anthropozoonosis that is endemic in most regions in Brazil. Despite the spread of the disease in recent years, ATL remains a neglected disease. Mucosal leishmaniasis (ML) is mainly caused by Leishmania (V.) brasiliensis agent, and usually occurs months or years after symptomatic or asymptomatic skin infection. Approximately 5% of patients with untreated cutaneous leishmaniasis will develop ML, a presentation that causes significant morbidity to patients. The mucosal leishmaniasis is a progressive disease that affects cartilage and bone structures of the nose and paranasal sinuses as well as other upper respiratory tract structures. Complications associated with ML have been described, but there is a lack of studies which evaluate the structural changes of the nose and paranasal sinuses in ML using radiological methods. Objective: To assess the degree of opacification of the paranasal sinuses in patients with treated mucosal leishmaniasis as well as any anatomic changes in the face associated with ML through multidector computed tomography scans (MDCT) of the sinuses, and compare the findings in this population with a control group. This study also aims at determining the prevalence of chronic sinusitis in patients with treated ML as well as finding probable predictive variables that may be related to the severity of sinus disease and CT findings. Methods: We evaluated 54 patients with treated ML who were submitted to MDCT of the sinuses, and compared with a control group of 40 patients who underwent MDCT of orbit. Analysis of the scans was performed from multiplanar reconstructions in the axial, coronal and sagittal views. The degree of sinus disease was assessed according to the Lund-Mackay criteria, in which a value was assigned to the degree of opacification of each sinus system and ostiomeatal complexes, and the scores from the mucosal leishmaniasis group were compared to the control group. A comparative analysis was then performed among patients in the mucosal leishmaniasis group, who were divided into 2 subgroups according to the presence (Lund-Mackay >= 4) or absence (Lund-Mackay < 4) of sinus disease, with 40 and 14 patients respectively. Following this subdivision, exploratory univariate analysis were performed to identify predictive variables that could be associated to the presentation of greater severity of sinus disease. The level of significance was defined as p <0.05. Results: Forty of the 54 patients with a history of ML (74.1%) had a tomographic score compatible with chronic sinusitis (Lund- Mackay >= 4). CT scans in the leishmaniasis and control groups demonstrated significant differences in terms of facial structural alterations. Patients from the mucosal leishmaniasis group showed more severe levels of partial opacification and pan sinus mucosal thickening 23/54 (42.6%), furthermore complete opacification of at least one paranasal sinus was only observed in the leismaniasis group. Patients from the mucosal leishmaniasis group with Lund-Mackay score >= 4 presented greater length of symptoms before treatment and more severe presentation of the disease at the diagnosis. Conclusion: CT scans of the sinus of patients with ML also presented several structural alterations, expressing the prominent destructive feature of the disease. The higher prevalence of chronic rhinosinusitis observed in CT scans of patients with treated ML in this study when compared to the control group suggests that ML can be seen as a risk factor for chronic rhinosinusitis in this population. Male sex, having the disease for more than two years before first treatment and/or a more severe presentation of ML at diagnosis, can be considered as predictive variables of chronic sinusitis in these patients

Flagelina, a subunidade estrutural dos flagelos bacterianos, pode ser empregada em estratégias vacinais como carregadora de epitopos antigênicos fusionados ou como adjuvante. Neste trabalho avaliamos a imunogenicidade e o potencial vacinal das flagelinas Salmonella enterica sorovar Typhimurium em camundongos BALB/c após administração pelas vias oral ou intraperitoneal. Os resultados indicam que animais imunizados pela via oral com linhagens flageladas de S. Typhimurium não desenvolvem respostas de anticorpos, sistêmicos ou secretados, anti-flagelina, por outro lado, ativam respostas celulares específicas para as flagelinas em função da via de administração utilizada. Observamos ainda que as diferentes flagelinas testadas apresentam efeito adjuvante quando co-administradas pela via nasal com a fímbria CFA/I de ETEC. Em suma, os resultados apresentados contribuem para um melhor conhecimento sobre as propriedades imunológicas e adjuvantes das flagelinas de S. Typhimurium e agregam informações para o uso racional dessas proteínas em formulações vacinais. / Flagellin, the structural subunit of bacterial flagella, can be used in vaccine development as a fused antigenic epitope carrier or as an adjuvant. In this work we evaluated the immunogenicity and vaccine approach of S. Typhimurium flagellin in BALB/c mice after administration by oral or intraperitoneal route. Our results indicate that mice immunized by oral route with flagellated S. Typhimurium strains do not develop any anti-flagellin antibody response, be it serum or secreted. On the other hand, specific anti-flagellin cellular response was observed depending on the chosen route of immunization with S. Typhimurium attenuated strain. Furthermore, all flagellins tested proved to be efficient adjuvants when co-administrated with CFA/I fimbriae by nasal route. Together, these results contribute to a better understanding of the immunological and adjuvant properties of S. Typhimurium flagellins and also provide information on the rational use of these proteins in vaccine development.

Le diabète de type 1 (DT1) est une maladie auto-immune caractérisée par la destruction sélective des cellules β pancréatiques entraînant une hyperglycémie et nécessitant un traitement par insulinothérapie à vie. La physiopathologie du DT1 est complexe et fait intervenir les cellules immunitaires innées et adaptatives dans la pathogenèse et la régulation du DT1. Alors que le développement du diabète peut être associé à des facteurs génétiques, des facteurs environnementaux sont également impliqués dans le déclenchement de cette maladie. Des études récentes ont mis en évidence le rôle du microbiote intestinal dans le développement ou la protection du DT1. Des modifications du microbiote ont par ailleurs été observées chez les patients DT1 avant le déclenchement de la maladie. Plusieurs études ont également décrit des altérations de la muqueuse intestinale chez les souris NOD et chez les patients DT1. Les cellules MAIT sont des lymphocytes T de type inné reconnaissant la molécule de MR1 et exprimant un TCR Va semi-invariant (Vα7.2-Jα33 chez l'homme et Vα19-Jα33 chez la souris). Les cellules MAIT sont activées par des métabolites bactériens, dérivés de la synthèse de la riboflavine. Leur particularité est de produire rapidement diverses cytokines telles que le TNF-α, l’IFN-γ et l’IL-17 et le granzyme B. La localisation et la fonction des cellules MAIT suggèrent qu'elles pourraient jouer un rôle clé dans le maintien de l'intégrité intestinale et le développement des réponses auto-immunes dirigées contre les cellules β. Dans l’ensemble, nos résultats chez les patients DT1 et chez les souris NOD montrent une activation anormale des cellules MAIT chez les patients DT1. Ces anomalies peuvent être détectées avant le déclenchement de la maladie. L'analyse des tissus périphériques de souris NOD souligne le rôle des cellules MAIT dans deux tissus, le pancréas et la muqueuse intestinale. Dans le pancréas, la fréquence des cellules MAIT est augmentée. Dans ce tissu les cellules MAIT semblent participer à la destruction des cellules β. Contrairement au pancréas, les cellules MAIT situées dans la muqueuse intestinale semblent jouer un rôle protecteur grâce à leur production de cytokines IL-22 et IL-17. Nos données chez les souris NOD Mr1-/-, dépourvues de cellules MAIT, soulignent le rôle protecteur des cellules MAIT lors du développement du DT1 en participant au maintien de l'intégrité intestinale. En outre, la présence d'altérations intestinales à mesure que la maladie progresse chez les souris NOD souligne l'importance des cellules MAIT dans le maintien de l'homéostasie intestinale. De manière intéressante, les cellules MAIT pourraient représenter un nouveau biomarqueur de la maladie et permettre de développer des stratégies thérapeutiques innovantes basées sur l’activation locale des cellules MAIT. / Type 1 diabetes (T1D) is an auto-immune disease characterized by the selective destruction of pancreatic islet β cells resulting in hyperglycemia and requiring a life-long insulin replacement therapy. The physiopathology of T1D is complex and still not entirely understood. Both innate and adaptive immune cells are involved in the pathogenesis and the regulation of T1D. While diabetes development can clearly be associated with genetic inheritance, environmental factors were also implicated in this autoimmune diseases. Recent studies have highlighted the role of the intestinal microbiota in the development or protection against T1D. Gut microbiota analyses in patients have shown differences before the onset of T1D. Moreover, several studies also described gut mucosa alterations in NOD mice and in T1D patients. MAIT (Mucosal Associated Invariant T) cells are innate-like T cells recognizing the MR1 molecule and expressing a semi-invariant receptor Vα chain (Vα7.2-Jα33 and Vα19-Jα33 in mice). MAIT cells are activated by bacterial metabolites, derived from the synthesis of riboflavin. Their particularity is to rapidly produce various cytokines such as TNF-α IFN-γ, IL-17 and granzyme B. The localization and the function of MAIT cells suggest that they could exert a key role in the maintenance of gut integrity, thereby controlling the development of autoimmune responses against pancreatic β cells. To summarize, our results in T1D patients and in NOD mice indicate an abnormal MAIT cell activation in this pathology, which occurs before disease onset. The analysis of peripheral tissues from NOD mice highlights the role of MAIT cells in two tissues, the pancreas and the gut mucosa. In the pancreas, MAIT cells frequency is elevated and they could participate to the β cells death. In contrast to the pancreas, in the gut mucosa MAIT cells could play a protective role through their cytokines production of IL-22 and IL-17. Our data in Mr1-/- NOD mice, lacking MAIT cells, reveal that these cells play a protective role against diabetes development and in the maintenance of gut mucosa integrity. Moreover, the presence of gut alteration as T1D progress in NOD mice underscores the importance of MAIT cells in maintaining gut mucosa homeostasis. Interestingly, MAIT cells could represent a new biomarker towards T1D progression and open new avenues for innovative therapeutic strategies based on their local triggering.

<p>Drug delivery to the nasal and ocular mucosa faces several obstacles. One of these is from the effective clearance mechanisms present in the nose and eye. Polymer gels with suitable rheological properties can facilitate the absorption of poorly absorbed drugs by increasing the contact time of the drug with the mucosa. This has been attributed to the rheological and mucoadhesive properties of the gel. The main objective of this thesis was to investigate the importance of these features for the anticipated in vivo contact time, here exemplified by the ocular and nasal routes of administration.</p><p>The in situ gelling polymer gellan gum was found to have a favourable rheological and in vivo performance. When administered in the nasal cavity of rats, a gel was formed that could remain at the site of administration for up to 4 hours. In addition, the epithelial uptake and transfer of a 3 kDa fluorescein dextran was higher than for a mannitol solution. Therefore, it was concluded that a gellan gum formulation should be a promising strategy for nasal drug delivery.</p><p>The potential mucoadhesive properties of a variety of polymer gels were investigated using a rheological method and by measuring the tensile force required to detach the gel from a mucosa. With both methods the rheological properties of the gel were a determining factor for the results obtained. The rheological method was found to have several limitations. One of these was that a positive response, interpreted as mucoadhesion, was only seen with weak gels. The tensile method could, in contrast, detect strengthening of the mucus only for strong gels. However, this method reflects the in vivo performance of the gel better than the rheological method.</p><p>Finally, dielectric spectroscopy was explored as a tool for investigating the likelihood of intimate surface contact between the gel and the mucus layer. This novel approach involved determining the ease with which a charged particle can pass the gel-mucus interface layer, and may enable the study of the events at the interface closer to the molecular level, than is possible with the rheological and tensile strength methods.</p>

Drug delivery to the nasal and ocular mucosa faces several obstacles. One of these is from the effective clearance mechanisms present in the nose and eye. Polymer gels with suitable rheological properties can facilitate the absorption of poorly absorbed drugs by increasing the contact time of the drug with the mucosa. This has been attributed to the rheological and mucoadhesive properties of the gel. The main objective of this thesis was to investigate the importance of these features for the anticipated in vivo contact time, here exemplified by the ocular and nasal routes of administration. The in situ gelling polymer gellan gum was found to have a favourable rheological and in vivo performance. When administered in the nasal cavity of rats, a gel was formed that could remain at the site of administration for up to 4 hours. In addition, the epithelial uptake and transfer of a 3 kDa fluorescein dextran was higher than for a mannitol solution. Therefore, it was concluded that a gellan gum formulation should be a promising strategy for nasal drug delivery. The potential mucoadhesive properties of a variety of polymer gels were investigated using a rheological method and by measuring the tensile force required to detach the gel from a mucosa. With both methods the rheological properties of the gel were a determining factor for the results obtained. The rheological method was found to have several limitations. One of these was that a positive response, interpreted as mucoadhesion, was only seen with weak gels. The tensile method could, in contrast, detect strengthening of the mucus only for strong gels. However, this method reflects the in vivo performance of the gel better than the rheological method. Finally, dielectric spectroscopy was explored as a tool for investigating the likelihood of intimate surface contact between the gel and the mucus layer. This novel approach involved determining the ease with which a charged particle can pass the gel-mucus interface layer, and may enable the study of the events at the interface closer to the molecular level, than is possible with the rheological and tensile strength methods.

Gastrointestinal microflora has been shown to have a bi-directional relationship with the host immune system. A variety of fermentable carbohydrate polymers largely pass through the small intestine, providing fermentable substrates for gut microflora. Dietary fibre supplementation may provide a strategy for manipulating the intestinal bacterial profile, changing the interaction with the mucosal immune system, thereby modulating the host immune system. We used a BBc rat animal model to evaluate the effects of oat bran and wheat bran dietary fibre on the immune system. Previous collaborative efforts have shown that these dietary fibres can change the intestinal microflora, with wheat bran fibre showing a greater ability to influence colonic microbial community diversity. We have shown that dietary wheat bran fibre led to reduced IL-4 levels in the liver and T lymphocyte numbers in the Mesenteric Lymph Node and may be involved in reduced IgA levels in the cecal contents. In addition, IgA in the cecal contents was decreased while MLN B cell numbers increased in response to dietary wheat bran fibre. It was observed that neither wheat bran or oat bran treatments exerted any pro-inflammatory effects, with oat bran actually improving antioxidant status. These results suggest that both oat and wheat bran fibre treatments induce changes in the intestinal microflora, and that the microflora changes due to wheat fibre are associated with immunomodulatory effects on the host. This type of dietary fibre supplementation could ultimately provide a potential strategy for promoting health through microflora-associated effects on the immune system.

Gemini surfactants are versatile gene delivery agents because of their ability to bind and compact DNA and their low cellular toxicity. The aim of my dissertation work was to develop non-invasive mucosal formulations of novel amino acid-substituted gemini surfactants with the general chemical formula C12H25(CH3)2N+-(CH2)3-N(AA)-(CH2)3-N+(CH3)2-C12H25 (AA= glycine, lysine, glycyl-lysine, lysyl-lysine). These compounds were formulated with a model plasmid DNA, encoding for interferon-γ and green fluorescent protein, in the presence of helper lipid, 1,2 dioleyl-sn-glycero-phosphatidyl-ethanolamine. Formulations were assessed in Sf 1 Ep epithelial cells. Among the novel compounds, plasmid/gemini/lipid (P/G/L) nanoparticles formulated using glycine- and glycyl-lysine substituted gemini surfactants achieved significantly higher gene expression than the parent unsubstituted compound. The key physicochemical properties, e.g. size, surface charge, DNA binding, and toxicity of P/G/L complexes were correlated with transfection efficiency. The presence of amino-acid substitution did not interfere with DNA compaction and contributed to an overall low toxicity of all P/G/L complexes, comparable to the parent gemini surfactant. A cellular uptake mechanistic study revealed that both clathrin- and caveolae-mediated uptake were major uptake routes for P/G/L nanoparticles. However, amino acid substitution in the gemini surfactant imparted high buffering capacity, pH-dependent increase in particle size, and balanced DNA binding properties. These properties may enhance endosomal escape of P/12-7NGK-12/L resulting in higher gene expression. Finally, the P/G/L complexes were incorporated into an in-situ gelling dispersion containing a thermosensitive polymer, poloxamer 407, and a permeation enhancer, diethylene glycol monoethyl ether (DEGEE). A 16% w/v poloxamer concentration produced a dispersion that gelled at body temperature and exhibited sufficient yield value to prevent formulation leakage from the vaginal cavity. The formulations were prepared with a model plasmid, encoding for red fluorescent protein, and administered topically to rabbit vagina. In agreement with our in vitro results, confocal microscopy revealed that glycyl-lysine substituted gemini surfactant exhibited higher gene expression compared to the parent unsubstituted gemini surfactant. This provided proof-of-concept for use of amino acid-substituted gemini surfactant in non-invasive mucosal (vaginal) gene delivery systems with potential therapeutic applications. These formulations will be developed with therapeutically relevant genes to assess their potential as genetic vaccines. In addition, new gemini surfactants will be developed by grafting other amino acids via glycine linkage to retain conformation flexibility and enhance endosomal escape of DNA complexes for higher transfection efficiency.